A phase II study of abiraterone in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer

Trial Profile

A phase II study of abiraterone in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisolone; Prednisone
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms CORAL
  • Most Recent Events

    • 11 Oct 2016 Results assessing clinical activity of abiraterone presented at the 41st European Society for Medical Oncology Congress.
    • 15 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 28 Jan 2016 Accrual to date is 88% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top